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EDITORIALS
Costly Choices for Treating Wilson’s Disease
W
hen the character Howard Beale, played by
Peter Finch in the 1976 movie Network,
shouted “I’m mad as hell and I’m not
going to take this anymore!”, he might have been
paraphrasing the blogs and comment strings, e-mail
notes, and telephone calls we received about the price
increases for chelation therapy for Wilson’s disease
(WD). The current outrage focuses on trientine
(Syprine). However, D-penicillamine (Cuprimine) is
also affected. The rights to manufacture and distrib-
ute these drugs have changed hands twice since 2000.
The current price for Syprine is $200 per 250-mg
capsule and Cuprimine costs $55-$60 per 250-mg
tablet.1 The annual cost for the average daily adult
dose of Syprine (1,000 mg) is $300,000, making it
the most costly treatment for any liver disease to
date. By contrast, the original producer of Syprine
and Cuprimine, Merck, kept consumer cost at $1
per 250-mg tablet for 20 years. While manufactur-
ing and distribution costs have risen, price increases
are not owing to research investment in product
improvement. Patient assistance programs exist and
have helped many, but not all, patients. Some insur-
ance companies are denying coverage for Syprine,
limiting access unless patients self-pay or receive
pharmaceutical company assistance.
How did this happen? Because the affected patient
population is small in number there is little driving
competition for the manufacture and distribution of
D-penicillamine or trientine in the United States. One
other U.S. manufacturer, Meda Pharm, produces D-
pencillamine, and it also has increased the price signifi-
cantly ($30 per 250-mg tablet). Some patients are
fearful that manufacturers will stop production at the
slightest provocation and they therefore hesitate to
voice opposition to the rising costs. Moreover, in the
orphan drug sector, generic drug manufacturers rarely
take over production once exclusivity rights have
expired.2 The second factor driving the price increase
is simply profit motive. Prices are raised because there
is currently no legal barrier to doing so. This situation
exists despite having orphan drug legislation in place
for more than 30 years. Though it is advantageous if
profits from drug sales are invested in research and
development for rare diseases, this may not always
occur.
With respect to assuring a supply of reasonably
priced D-penicillamine or trientine, patient advocates
could petition government to put a ceiling on price.
However, there is always the risk that pharmaceutical
companies will abandon manufacture of a medication
if there is no profit. Other manufacturers could enter
the market, but the economics for this are tenuous at
best. The U.S. Food and Drug Administration (FDA)
could fast track approval for sales of medications pro-
duced abroad for rare diseases in the United States,
but assurance of adequate production standards is nec-
essary. Alternatively, the federal government could
become the single purchaser and provider of medica-
tions for rare diseases such as WD. Recently, in Can-
ada, where Syprine lacks regulatory status and is
available only through Health Canada’s “Special Access
Programme” (SAP; whereby the patient routinely pays
for medication and provincial support is available only
exceptionally), public advocacy led to the addition of a
second formulation of trientine to the SAP list to pro-
vide some choice about cost.3 Public discussions of
payment for “old” orphan drugs such as trientine are
beginning to take place.
Without regulation, costs of treating the few
patients with rare diseases will outstrip the cost of care
for other diseases in the general population. A recent
New York Times editorial4 highlighted the $300,000
annual cost of ivacaftor, a new medication for a subset
of cystic fibrosis patients. Therefore, we need to con-
tain costs or face inequitable access to best therapies.
What can our patients with WD do? Solving this
sudden crisis by legislative action will not be swift
given that regulatory or policy change is required. Fur-
thermore, any new legislation must not wipe out
incentives for companies to enter into research and
development of treatments for patients with rare dis-
eases. Indeed, the boom in orphan drug pricing has
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coincided with an increase in FDA orphan drug desig-
nations from 100 in 2003 to a record 260 in 2013.5
Reasoned and insistent advocacy by hepatologists is
urgently required.
For many WD patients, the financial crisis is imme-
diate and a serious personal health crisis looms on the
horizon. Conversion to far less costly zinc salts is a via-
ble option for some. Following initial development
with zinc sulfate in The Netherlands by Schoewink
and Hoogenraad and further study of zinc acetate in
the United States by Brewer et al., the FDA approved
Galzin as maintenance therapy for WD in 1997. Since
then, other published studies have shown long-term
efficacy of zinc as maintenance therapy for WD6 and,
possibly, as first-line treatment for some neurologically
affected patients.7 Current American Association for
the Study of Liver Diseases and European Association
for the Study of the Liver guidelines suggest using che-
lating agents at the outset of therapy for all sympto-
matic patients, but acknowledge zinc as a maintenance
therapy for WD.8,9
Why hasn’t zinc maintenance therapy for all patients
with WD caught on? Zinc must be taken two to three
times daily, well away from meals for best absorption.
Single daily dosing of zinc acetate is not effective.10
The FDA approved labeling for Galzin set dosing at
three times daily based on data showing negative cop-
per balance and good zinc absorption with this regi-
men. Among “treatment failures” with zinc, many had
issues with adherence.11,12 Dyspepsia is limiting for
some patients, but can sometimes be solved by changes
in timing of dose, using a different zinc formulation
or by coadministration with protein.
How does zinc stack up against chelation therapy
for maintenance treatment of WD patients? One large
retrospective study from Germany presents data favor-
ing chelation therapy over zinc for maintenance,
mainly for patients with liver disease.13 The retrospec-
tive nature of the study is problematic given that
details of treatment failures and nonadherence are not
available. In the extensive experience of the authors of
this editorial in treating WD, we recall only rare treat-
ment failures of patients who were adherent to their
long-term zinc therapy. Individuals incapable of
responding well to zinc therapy may exist, but these
should be identified by early testing. WD patients on
long-term zinc therapy, or any maintenance therapy,
still require regular monitoring.
Another reason for poor utilization of zinc as main-
tenance therapy in WD is that physicians are uncertain
about how to make the conversion. It is not extremely
complicated. The patient needs to be clinically stable,
preferably with normal liver biochemistries. No lead-in
to zinc therapy is needed, neither tapering of the che-
lation therapy nor ramping up of zinc dosage. How-
ever, “testing the waters” and trying on a particular
zinc salt before adopting zinc monotherapy will help
patients feel confident that dyspepsia will not likely
interfere with their long-term use of zinc. Second,
because gastrointestinal absorption differs for each zinc
salt, patients should be examined for increased plasma
zinc and urine zinc excretion over a 24-hour period
(while off of chelation) as a demonstration of effective
zinc absorption. Parameters used to judge treatment
efficacy include serum copper and ceruloplasmin (and
the estimated non-ceruloplasmin-bound copper) and
serum aminotransferases. Importantly, patients on zinc
therapy typically have lower urinary copper excretion
than those on chelation therapy, most <100 lg/day.
After conversion to zinc therapy, patients should be
regularly monitored for adherence to treatment. Long
term, patients should be monitored for copper defi-
ciency, especially those previously on chelation therapy
for many years.
The predicament with trientine accessibility may have
a silver lining. It provides the opportunity for a one-off
natural experiment. We can and should take this oppor-
tunity when some of our WD patients convert to zinc
maintenance therapy to study in detail the pros and
cons of treatment conversion and examine the risks and
benefits of long-term treatment with zinc prospectively.
Reports of some increased incidence of prostate cancer
or changes in immune function appear to reflect weak
associations. Such a prospective study to collect data on
zinc-treated patients is being organized.
So, when our WD patients are “mad as hell” at costs
for chelation therapy and are afraid they cannot afford
medication or that production will be stopped, we must
take a stand and help them find a viable solution. For-
tunately, for some patients stable on chelation therapy
who need to change treatment because they can no lon-
ger afford their current therapy, zinc is a readily avail-
able treatment option. However, newly diagnosed
patients in need of rapid copper reduction by chelation
therapy may not be able to afford this therapy, given
current costs and insurance company denials of cover-
age. Previous experience indicates that not having trien-
tine as a treatment option can be extremely problematic
for some patients.14 For those WD patients in whom
both D-penicillamine and zinc are not effective or safe
treatment options, trientine is life-saving. We must
strongly advocate for all our patients with orphan or
rare diseases such as WD so that they may always
receive the best available treatment.
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